Atomoxetine becomes first selective norepinephrine reuptake inhibitor to enter clinical use in the U.S. for attention deficit hyperactivity disorder

Atomoxetine has become the first selective norepinephrine reuptake inhibitor to become available in the U.S., giving psychiatrists a nonstimulant option for treatment of attention deficit hyperactivity disorder. The drug is also the first to have effectiveness proven in trials involving children, adolescents, and adults.

Atomoxetine is produced in capsule form and can be taken once or twice daily. Clinical trials showed that it can provide full-day relief from symptoms without causing insomnia in most children and adolescents.

In the U.S., experts estimate that the disorder affects 3 to 7 percent of school-age children. Because roughly 60 percent of affected children retain symptoms in adulthood, roughly 4 percent of American adults are impaired by symptoms of the disorder.

The drug should not be taken concurrently with a monoamine oxidase inhibitor and should not be used by patients with narrow angle glaucoma. Most participants in clinical trials who experienced side effects were able to continue in the trial rather than withdraw. The most common side effects in children and adolescents were decreased appetite, nausea, vomiting, tiredness, dyspepsia, dizziness, and mood swings. In adults, the most common side effects were sleep difficulties, dry mouth, decreased appetite, constipation, dyspepsia, nausea, dizziness, difficulty with urination, painful menstrual periods, and sexual difficulties.



DOLについて - 利用規約 -  会員規約 -  著作権 - サイトポリシー - 免責条項 - お問い合わせ
Copyright 2000-2025 by HESCO International, Ltd.